The CDH3-specific clone was shown to specifically kill an HLA-A2+ breast cancer cell line (MCF-7), and not an HLA-A2+ metastatic melanoma cell line (MM909.24; obtained from the Center for Cancer Immune Therapy, Herlev Hospital, Copenhagen, Denmark) in a 51Cr-release assay after 4 h (Fig. 3H). This evidence concerns the gene CDH3 and metastatic melanoma.